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Background: To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist
exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM).
Methods: We conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care
data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients
who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with
follow-up data available until December 2012. Three treatment groups were: EBID with oral antidiabetes drugs
(OADs) (EBID, n = 2804), insulin with OADs (Insulin, n = 28551), and those who changed medications between EBID
and insulin or had combination of EBID and insulin during follow-up, along with OADs (EBID + insulin, n = 7870).
Multivariate Cox-regression models were used to evaluate the association of treatment groups with the risks of
macrovascular events.
Results: During a median 3.5 years of follow-up, cardiovascular event rates per 1000 person-years were significantly
lower for the EBID and EBID + insulin groups compared to the insulin group (HF: 4.4 and 6.1 vs. 17.9; MI: 1.1 and 1.2
vs. 2.5; stroke: 2.4 and 1.8 vs. 6.1). Patients in the EBID/EBID + insulin group had significantly reduced risk of HF, MI
and stroke by 61/56%, 50/38% and 52/63% respectively, compared to patients in the insulin group (p < 0.01).
Conclusions: Treatment with exenatide, with or without concomitant insulin was associated with reduced
macrovascular risks compared to insulin; although inherent potential bias in epidemiological studies should
be considered.
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Treatment of type 2 diabetes mellitus (T2DM) needs to ad-
dress disease progression and balance the pharmacological
efforts that limit hyperglycaemia against the increased risks
of adverse effects including hypoglycaemia and weight
gain. As patients with T2DM experience increased risk
of cardiovascular (CV) morbidity and mortality over time,
treatment strategies should ideally also address CV risk
factors including body weight, blood pressure and lipids* Correspondence: sanjoy.paul@qimrberghofer.edu.au
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unless otherwise stated.[1,2]. Initially, most patients take oral antidiabetes drugs
(OADs) to combat hyperglycaemia. Once OADs fail to
control hyperglycaemia, transition to injection of exogen-
ous long-acting insulin has been the standard next step,
introducing challenges including labour-intensive manage-
ment, hypoglycaemia and weight gain.
Since their introduction, incretin-based therapies includ-
ing the oral dipeptidyl peptidase 4 (DPP-4) inhibitors
and injectable glucagon-like peptide-1 receptor (GLP-1R)
agonists have attracted attention as treatment alternatives
with unique mechanisms of action [2-8]. GLP-1R agonists
offer particular promise for patients with T2DM because
of potential cardioprotective effects. A large body of pre-is is an Open Access article distributed under the terms of the Creative
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risk with GLP-1R agonists via mechanisms including re-
duced body weight and adiposity [9-14], decreased blood
pressure (BP) [11,15], improved endothelial and myocar-
dial function [16-18], improved functional recovery of fail-
ing and ischemic hearts, increased diuresis and natriuresis,
and reduced circulating lipids [18-21]. In humans with
T2DM and congestive heart failure, GLP-1R agonists were
reported to improve myocardial function. In patients with
low left ventricular ejection fraction (LVEF) after acute
myocardial infarction, GLP-1 infusion improved LVEF and
global and local wall indices [4,15]. Using a large patient-
level data set from the United States, Best et al. reported
significantly reduced rates of HF, MI and stroke in patients
treated with exenatide for at least 31 days compared to
those treated with insulin [22,23]. A recent epidemio-
logical study based on Danish registry data reported sig-
nificant risk reduction for mortality in patients receiving
DPP-4 plus metformin (MET) compared to those treated
with MET plus sulphonylurea (SU), although the observed
risk reduction in patients treated with MET plus GLP-1R
agonist was not significant [24]. However, the SAVOR-
TIMI and EXAMINE study did not show any significant
beneficial effects of treatment with DPP-4 inhibitors on
macrovascular outcomes [25,26].
As a relatively new treatment for hyperglycaemia in pa-
tients with T2DM, the long-term effect of GLP-1R agon-
ism on CV outcomes in clinical trials or actual practice
has not been established. Whilst numerous large CV out-
come trials are ongoing to evaluate CV outcomes with
GLP-1R agonists in patients with T2DM, the results from
such trials will not be known before 2015, and will not
demonstrate the real-world effects of GLP-1R agonism.
The aim of our study was to evaluate CV risks in patients
with T2DM treated with the GLP 1-R agonist exenatide
twice daily (EBID) and/or insulin in a large, nationally-
representative longitudinal ambulatory-care medical record
database. Specific aims were to evaluate: (1) event rates of
HF, MI, stroke in patients treated with EBID and conven-
tional oral anti-diabetic drugs (OADs) (EBID group), insu-
lin plus OADs (insulin group), and those who changed
medications between EBID and insulin or had combination
of EBID and insulin during follow-up, along with OADs
(EBID + insulin); (2) risks of HF, MI, stroke and combined
event of MI or stroke in patients belonging to EBID and
EBID + insulin groups compared to those in the insulin
group, adjusting for various risk factors.
Methods
Data source
Data for this study were obtained from General Electric
Centricity database, which collate patient-level informa-
tion from a network of outpatient offices in the United
States in the Medical Quality Improvement Consortium(MQIC). MQIC practices use the Centricity Electronic
Medical Record. These data represent more than 40 US
states and a variety of ambulatory medical practices, in-
cluding solo practitioners, community clinics, academic
medical centres, and large integrated delivery networks.
The database has been extensively used for academic re-
search in the United States [27-29]. MQIC consists of
over 17,000 physicians and other providers, of whom ap-
proximately 70% are primary care providers.
From more than 1.2 million patients with confirmed
T2DM, a cohort of patients was selected who received
first prescription of EBID or insulin between June 2005
and May 2009, with follow-up data available till Decem-
ber 2012. The cohort selection criteria included: (1)
age ≥ 18 years at the start date of the cohort (index date),
(2) no missing data on age, sex, ethnicity, smoking sta-
tus, and HbA1c at index date, (3) at least two consecu-
tive prescriptions of EBID or insulin on and immediately
after the index date, and (4) complete information on
event dates for HF, MI and stroke following the index
date along with International Classification of Diseases,
Ninth edition (three-digit ICD-9 codes) for these events.
Any event with an ‘undefined’ reference was excluded.
Patients with any prescription for a DPP-4 inhibitor
were excluded to avoid residual confounding effects of
another incretin therapy.
Under the above selection criteria, we obtained a co-
hort of 183,125 patients who received the first prescrip-
tion of insulin or EBID between June 2005 and May
2009. Owing to significant differences in the distribu-
tions of age and glycated haemoglobin (HbA1c) on index
date between treatment groups, a new cohort of 39,225
patients was identified with matching for age and HbA1c
at index date, belonging to three treatment groups:
(a) insulin group, n = 28,551, (b) EBID group, n = 2,804,
and (3) EBID + insulin group, n = 7,870. Patients in the
EBID + insulin group could start either of the drugs on
the index date and needed at least two prescriptions of
the other drug during the follow-up. A Coarsened Exact
Matching method (generalisation of the propensity score
method) was used to create matched data in the treat-
ment groups [30].
Baseline demographic and clinical information in-
cluded age, sex, ethnicity, smoking status, duration of
diabetes (DD), body mass index (BMI), and systolic and
diastolic blood pressure. Laboratory measurements in-
cluded measures of HbA1c within a 3-month window
prior to the index date. Complete information on OADs,
anti-hypertensive and cardioprotective medications (CPMs)
over time were obtained along with dates of prescriptions.
The CPMs included statins, angiotensin-converting en-
zyme inhibitors (ACE), angiotensin receptor blockers
(ARB) and beta blockers. History of cardiovascular dis-
eases and renal diseases (including ICD 9 codes 585.1
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This study was exempt from ethics approval from an in-
stitutional review board and informed consent because,
according to the US Department of Health and Human
Services Exemption 4 (CFR 46.101(b)(4)), the research in-
volved the study of existing data, and the subjects could
not be identified directly or through identifiers linked to
the subjects.
Statistical methods
The basic statistics on patients’ characteristics were pre-
sented by number (%), mean (standard deviation: SD) or
median (inter-quartile range: IQR). Event rates per 1,000
person years were calculated for specific CV events
along with their 95% confidence intervals (CI). The com-
posite event of MI or stroke was defined as the first oc-
currence of either of MI or stroke during follow-up. The
time to composite events was the time to the occurrence
of first of the composite events. To evaluate the risks
of CV events in patients in EBID and EBID + insulin
groups compared to those in the insulin group, adjusted
Cox regression models were fitted. Multivariable models
included gender, ethnicity, age at the start of cohort,
BMI, HbA1c, systolic and diastolic blood pressure on
the index date, history of CV disease, any renal disease
prior to index date or during follow-up, use of MET, SU,
CPMs or antihypertensive medications, and the duration
of diabetes (calculated at index date from the available
disease onset days). Separate models were fitted for all
patients, for patients without history of CV diseases and
for patients without history of CV diseases and renal dis-
eases before or after the index date. The proportionality
assumption in the Cox regression models was tested,
and stratified multivariable Cox regression models were
fitted with age-quartiles as a stratifying factor. As the
inclusion criteria in the cohort included availability of
2 prescriptions within 60 days of index date, the “time to
event” for the survival analyses were adjusted accord-
ingly to avoid possible “immortality bias”. As the treat-
ment of either drug could start anytime in the EBID +
insulin group, there is a potential for time bias in the
context of survival analysis. This aspect was dealt with
using a time-varying covariate. As a part of sensitivity
analyses, separate risk evaluations were performed for
patients taking metformin only (n = 26052), and also by
baseline BMI categories.
The number of recorded prescriptions for EBID and
insulin during follow-up were obtained, and the mini-
mum duration of treatment with EBID and insulin were
calculated assuming a prescription is for at least one
month. As a part of sensitivity analyses, to evaluate the
possible association of duration of treatments with the
risk of events, separate multivariate regression modelswere fitted by adding the treatment duration variables to
the aforementioned multivariate models. Separate sub-
group analyses were also conducted among patients
taking MET or SU and HbA1c above 58.5 mmol/mol
(7.5%) and 63.9 mmol/mol (8%) at index date.
Results
In the cohort of 39,225 patients, mean (SD) age was 58
(13) years, 46% were male, 44% were Caucasian, 51%
were current or ex-smokers, and 12% had a CV disease
history before initiating EBID or insulin. Overall, 4%
(n = 1576) of patients had evidence of renal disease be-
fore initiation of EBID or insulin. The proportions of
patients with renal disease during follow-up in insulin,
EBID and EBID + insulin groups were 14.2%, 4.7% and
6.5%, respectively. The proportions of patients with
BMI ≥30 kg/m2 (obese) were significantly higher (89%)
in the EBID and EBID + insulin groups compared to the
insulin group (65%, Table 1). The median HbA1c and
mean systolic blood pressure (SBP) levels were similar
between the groups at the start of the cohort. Median
duration of diabetes at index date was 1 year in all
groups, with proportions of patients with DD above
5 years in insulin, EBID and EBID + insulin groups at
6%, 8% and 11% respectively. Overall median follow-up
time was 3.5 years.
Proportions of patients with previous and current (post-
index) CV events along with rates (per 1000 person-years)
of individual events are presented in Table 2. Rates of HF,
MI, and stroke were higher among patients in insulin
group compared to those in the EBID or EBID + insulin
groups. The proportion of patients with history of HF was
higher in the insulin group (3.2%) than in the EBID group
(1.7%) and EBID + insulin group (2.4%). Among those
without HF history (n = 38,085), rates of HF (per 1000
person-years) in insulin, EBID and EBID + insulin groups
were 17.1, 4.1 and 5.7, respectively. Compared to insulin,
patients in EBID and EBID + insulin groups had 66% (haz-
ard ratio (HR) CI: 0.22, 0.52) and 60% (HR CI: 0.32, 0.50)
less risk of HF, respectively, after adjusting for covariates
(Table 3). Patients with a higher BMI (HR: 1.03, p < 0.01)
and the history or incidence of renal disease during
follow-up (n = 5952, HR: 2.11, p <0.01) had increased HF
risks. Male patients had no increased risk of HF (HR: 1.10,
p = 0.14). Current and ex-smokers had 50% and 38%
increased risk of HF (p < 0.01 in both cases). Among
patients without CV disease history (n = 34,672) and
without history of renal disease (n = 33,744), similarly
reduced risks of HF were observed in EBID and EBID +
insulin groups.
Only 1% (n = 381) of patients had a history of MI,
most in the insulin group (286 of 381). Among those
without MI history (n = 38,844), rates of MI (per 1000
person years) in the insulin, EBID and EBID + insulin
Table 1 Characteristics of patients at the initiation of EBID or insulin treatment
Insulin EBID EBID + Insulin
N 28551 2804 7870
Maleπ 13562 (48) 1130 (40) 3401 (43)
Ageα 59 (14) 56 (11) 56 (11)
Diabetes duration (year)β 1.0 (0, 1) 1.0 (0.2, 1.8) 1.0 (0.1, 2.0)
Diabetes duration (year)α 1.2 (2.2) 1.6 (2.2) 1.8 (2.7)
White Caucasianπ 12145 (43) 1214 (43) 3898 (50)
Black 3482 (12) 119 (4) 445 (60)
Hispanic 956 (3) 36 (1) 103 (2)
Ex-smokerπ 8033 (33) 813 (35) 2452 (37)
Current smokerπ 4499 (19) 321 (14) 874 (13)
BMI (kg/m2)α 34.1 (8.3) 38.8 (7.9) 38.6 (7.8)
Overweight (BMI > 30 kg/m2)π 5759 (24) 245 (10) 691 (10)
Obeseπ 15949 (65) 2186 (89) 6210 (89)
SBP (mmHg)α 131 (19) 130 (16) 130 (16)
DBP (mmHg)α 75 (11) 78 (10) 77 (10)
HbA1c (mmol/mol)Ω 62.8 59.6 63.9
HbA1c (mmol/mol)β 58.5 (50.8, 70.5) 56.3 (48.6, 66.1) 59.6 (50.8, 71.6)
HbA1c ≥ 7 %π 19804 (69) 1708 (61) 5606 (71)
LDL-C (mmol/L)α 5.34 (2.11) 5.40 (1.98) 5.16 (1.96)
Triglyceride (mmol/L)β 8.16 (5.43, 12.32) 9.15 (6.43, 12.93) 9.27 (6.44, 13.43)
Follow-up (year)β 3.4 (1.8, 4.5) 3.3 (1.3, 4.5) 3.5 (3.0, 4.8)
Medication
Metforminπ 16549 (58) 2534 (90) 6969 (89)
Sulfonylureaπ 12291 (43) 1682 (60) 5309 (67)
Thiazolidinedioneπ 8589 (30) 1348 (48) 4218 (54)
ACE/ARBπ 22210 (78) 1990 (71) 6116 (78)
Beta Blockerπ 15156 (53) 1108 (40) 3444 (44)
Statinπ 23037 (81) 2355 (84) 6964 (88)
Anti-hypertensiveπ 24513 (86) 2339 (83) 6916 (88)
Aspirin 18683 (65) 1672 (60) 5467 (70)
Disease history prior to index date
Renalπ 1187 (4.16) 57 (2.03) 332 (4.22)
HFπ 901 (3.16) 48 (1.71) 191 (2.43)
MIπ 286 (1.00) 22 (0.78) 73 (0.93)
Strokeπ 351 (1.23) 14 (0.50) 82 (1.04)
IHDπ 1865 (6.53) 184 (6.56) 702 (8.92)
PVDπ 581 (2.03) 37 (1.32) 170 (2.16)
Anginaπ 160 (0.56) 24 (0.86) 70 (0.89)
αMean (SD); β Median (Q1, Q3); πN(%),ΩMean.
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tients without history of cardiovascular and renal dis-
eases, compared to insulin group, patients in the EBID
and EBID + insulin group had a 77% (HR CI: 0.06, 0.95)
and a 55% (HR CI: 0.28, 0.85) reduced risk of MI,respectively, after adjusting for covariates (Table 3).
Smoking and higher SBP was significantly associated
with increased risk of MI (data not shown). Patients tak-
ing MET had a 44% reduced risk of MI (p < 0.01). How-
ever, the observed 27% increased MI risk associated with
Table 2 Proportions of patients with cardiovascular events before initiation of treatment and during follow-up and the
rates (per 1000 person years) along with 95% confidence intervals of cardiovascular events, by treatment groups
Insulin EBID EBID + Insulin
Previous Current Previous Current Previous Current
HF N (%) 901 (3.16) 2094 (7.33) 48 (1.71) 49 (1.75) 191 (2.43) 195 (2.48)
Rate (CI) - 17.87 (17.00, 18.78) - 4.38 (3.17, 6.05) - 6.13 (5.30, 7.07)
MI N (%) 286 (1.00) 312 (1.09) 22 (0.78) 14 (0.50) 73 (0.93) 39 (0.50)
Rate (CI) - 2.54 (2.23, 2.89) - 1.06 (0.55, 2.03) - 1.15 (0.82, 1.60)
Stroke N (%) 351 (1.23) 803 (2.81) 14 (0.50) 26 (0.93) 82 (1.04) 62 (0.79)
Rate (CI) - 6.12 (5.62, 6.65) - 2.35 (1.52, 3.64) - 1.84 (1.41, 2.39)
MI or Stroke N (%) 620 (2.17) 1087 (3.81) 36 (1.28) 40 (1.43) 150 (1.91) 99 (1.26)
Rate (CI) 8.50 (7.92, 9.13) 3.42 (2.38, 3.60) 2.93 (2.38, 3.60)
Previous: Event prior to the index date, Current: Event after the index date.
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duction for MI was observed in these treatment groups
for patients with a history of cardiovascular diseases.
Among 447 (1.1%) patients with a history of stroke,
351 (79%) belonged to the insulin group (Table 1). Over-
all, 891 (2.3%) patients had at least one event of non-
fatal stroke during follow-up, with a rate (per 1000 per-
son years) of 4.85; 90% (n = 803) of events occurred in
the insulin group. The rate of stroke was nearly threefold
higher in the insulin compared to the other treatment
groups (Table 2). Among those without history of renal
and cardiovascular diseases, compared to the insulin
group, patients in the EBID and EBID + insulin groups
had a 63% (HR CI: 0.18, 0.75) and a 74% (HR CI: 0.16,Table 3 The hazard ratios (95% CIs) for cardiovascular events
to those treated with insulin, after adjusting for covariates, f
history of cardiovascular diseases and without renal diseases
All patients Without
N = 39,225 N = 34,67
HR (CI) p-value HR (CI)
HF
EBID vs Insulin 0.34 (0.22, 0.52) <0.001 0.34 (0.22
EBID + Insulin vs Insulin 0.40 (0.32, 0.50) <0.001 0.40 (0.32
MI
EBID vs Insulin 0.52 (0.23, 1.19) 0.12 0.24 (0.06
EBID + Insulin vs Insulin 0.65 (0.44, 0.98) 0.038 0.52 (0.31
Stroke
EBID vs Insulin 0.50 (0.28, 0.84) 0.010 0.36 (0.18
EBID + Insulin vs Insulin 0.38 (0.27, 0.54) <0.001 0.27 (0.17
MI or Stroke
EBID vs Insulin 0.50 (0.32, 0.79) 0.003 0.33 (0.18
EBID + Insulin vs Insulin 0.44 (0.34, 0.57) <0.001 0.33 (0.23
Adjusted for gender, ethnicity, age at the start of cohort, duration of diabetes, BMI,
disease, any renal disease prior to index date or during follow-up, use of metformin0.42) reduced risk of stroke, respectively (Table 3).
Higher SBP was significantly associated with increased
risk of stroke (<0.001), whereas MET had a protective
effect on stroke (HR CI: 0.61, 0.98). Treatment with
EBID was associated with similar significantly reduced
risk of composite event of MI or stroke (Table 3).
Among patients taking SU (n = 19282, 49%), the ob-
served adjusted risk reductions for HF, MI, stroke and
MI or stroke in the EBID and EBID + insulin groups
were similar to those observed in the overall analysis.
Among all patients, patients with renal diseases had
113% (p < 0.01) and 57% (p = 0.004) higher risk of HF
and MI respectively. Renal disease was not associated
with the risk of stroke (data not shown). HbA1c as ain patients treated with EBID or EBID + insulin compared
or all patients, and separately for patients without the
before index date and during follow-up
previous CVD Without previous CVD & renal diseases
2 N = 33,744
p-value HR (CI) p-value
, 0.52) <0.001 0.32 (0.21, 0.50) <0.001
, 0.50) <0.001 0.35 (0.28, 0.45) <0.001
, 0.99) 0.049 0.23 (0.06, 0.95) 0.043
, 0.91) 0.021 0.45 (0.28, 0.85) 0.011
, 0.74) 0.005 0.37 (0.18, 0.75) 0.006
, 0.42) <0.001 0.26 (0.16, 0.42) <0.001
, 0.63) 0.001 0.33 (0.18, 0.63) 0.001
, 0.47) <0.001 0.32 (0.22, 0.46) <0.001
HbA1c, systolic and diastolic blood pressure on the index date, history of CV
(MET), sulphonylurea (SU), and CPMs or antihypertensive medications time.
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(7.5%) at baseline was not significantly associated with
the risk of cardiovascular events.
In our study cohort, 26052 (66.4%) patients were on
metformin treatment. In patients treated with metformin,
similar risk profile for MI, HF or stroke were observed in
the EBID and EBID + insulin group, compared to those in
the insulin group - the HR (95% CI; p) for composite of
MI or stroke for EBID and EBID + insulin groups was 0.54
(0.34, 0.88; p = 0.012) and 0.44 (0.33, 0.59; p < 0.01)
respectively.
The BMI at baseline in the insulin group was relatively
lower than the other two groups (34 kg/m2) with 89%
overweight or obese at baseline. We conducted additional
analyses with baseline BMI categories with patients with
“normal weight” as reference category. The risk for com-
posite of MI or stroke in overweight and obese patients
were not significantly higher compared to those in the
normal weight category, after adjusting for other factors.
Also, the rates/1000 person years of individual cardiovas-
cular events were not significantly different by BMI cat-
egories (normal weight, overweight and obese) irrespective
of treatment groups in the study cohort.
The mean (SD) and median (IQR) number of recorded
insulin prescriptions during follow-up were 9 (9) and 7 (4,
13) respectively, with minimum median (IQR) 28 (6, 46)
months of duration of insulin treatment in the insulin
group. The mean (SD) and median (IQR) number of pre-
scriptions in the exenatide group were 2.7 (1.7) and 2 (2, 3)
respectively, with minimum median (IQR) 4 (3, 13) months
of duration of exenatide treatment in the exenatide group.
In the EBID + insulin group, the median (IQR) number of
exenatide prescriptions was 3 (2, 4) and the minimum dur-
ation of exenatide treatment was 5 (3, 23) months. The
minimum median (IQR) duration of insulin treatment in
this group was 28 (2, 48) months. Longer duration of treat-
ment with EBID was associated with significant reduced
risk of HF, MI and stroke for analyses of patients with and
without a history of cardiovascular diseases and renal dis-
eases. Duration of insulin treatment was not associated
with the risk of the cardiovascular events.
Discussion
Our retrospective cohort study, based on a large age and
HbA1c matched nationally-representative T2DM popu-
lation data source with median follow-up of 3.5 years,
showed that treatment with the GLP-1R agonist EBID
with or without insulin was associated with reduced
rates and risks of major macrovascular events compared
with an insulin-treated cohort. This comparative longitu-
dinal study demonstrated for the first time (to the best
of our knowledge) that patients with T2DM who are
treated with EBID, in addition to OADs, have lower
rates and comparative risks of HF, MI and stroke thanthose treated with conventional combination treatment
of insulin with OADs. As best as could be accounted for,
cardiovascular risk reduction in patients treated with
EBID was independent of variations in risk factors and
comorbidities before and during follow-up.
Overall, 49% and 36% of patients had HbA1c above
58.5 mmol/mol (7.5%) and 63.9 mmol/mol (8%) respect-
ively at the index date. We observed that patients with
HbA1c above 58.5 mmol/mol (7.5%) in the EBID and
EBID + insulin groups had significantly lower risks of
HF and MI or stroke than analogous patients in the in-
sulin group. Separate sub-group analyses for patients
above and below an HbA1c of 63.9 mmol/mol (8%), pa-
tients without history of CV and renal diseases, and pa-
tients using MET/SU produced similar risk estimates
for CV events in the EBID and EBID + insulin groups.
These findings suggest that treatment with GLP-1R ago-
nists may be associated with reduction in cardiovascular
risk, when added with other conventional anti-diabetic
drugs, after eliminating potential residual effects of
other diseases, concomitant medications, and baseline
glycaemic control.
Despite differences in follow-up time and comparator,
observed event rates for HF, MI and stroke in our study
were consistent with those reported by Best et al.
[22,23]. Best et al. [22] evaluated the risk of MI, stroke
and coronary revascularisation in patients treated with
EBID versus other anti-diabetes drugs combined over a
shorter period.
Mogensen et al. [24] reported significantly lower event
rates for cardiovascular death and combined end point
of MI, stroke and CV death among patients treated with
DPP-4 inhibitors and GLP-1R agonist in addition to
MET, compared to those treated with insulin and SU
[24]. GLP-1R agonist in combination with MET was re-
ported to have lower (but non-significant) risk ratio esti-
mates for CV death, all cause mortality and combined
end point during 2.1 years of median follow-up. In the
absence of mortality data, our data are not directly com-
parable to that reported by Mogensen et al. However, in
our subgroup analyses with patients taking MET and/or
SU during median (IQR) 3.5 (2.0, 4.6) years of follow-up,
the signal of risk reduction in patients treated with GLP-
1R agonist is in line with the reported study.
Recent pre-clinical and basic science literature reports
an array of beneficial findings with the GLP-1 receptor
agonist exenatide [31-34]. These findings are broad and
positively set the background for inflammatory state,
cardiac function impacting both diastolic and systolic
heart failure, peripheral vascular function and blood
pressure control, and acute states of myocardial ische-
mia. Taken together, one could anticipate a positive
impact on CV outcomes in a clinical setting, with the
current epidemiological analysis suggestive of such a
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needed to evaluate the possible extra-glycaemic benefits
of treatment with GLP-1 receptor agonists.
The primary strength of this study was the large co-
hort of patients treated with EBID and/or insulin for the
first time between 2005 and 2009 and followed for a me-
dian 3.5 years, with complete data on risk factors at the
start of the cohort. Inclusion of an independent group of
patients receiving both insulin and EBID or moving be-
tween these treatments was a novel aspect of this study
and ensured that data on patients failing EBID were cap-
tured. Among 7870 patients in the EBID + insulin group,
70% initiated insulin treatment on or after the first pre-
scription of exenatide. Patients initiating insulin before
exenatide (n = 2334) had a significantly higher rate of HF
per 1000 person years (rate: 9.01 vs 4.97). However, rates
of MI and stroke were similar.
Another important strength of this study was extensive
tracking of any CV or renal disease and reliable informa-
tion on smoking status. Although it is not possible to
account for all possible confounding factors in any lon-
gitudinal clinical epidemiological study, we adjusted for
available relevant covariates in our risk analyses. Separ-
ate analyses were also conducted excluding patients with
a history of CV disease and those with any renal disease.
The large study population provided a representative
source cohort that reflected common clinical practice
for T2DM across the United States and provided ad-
equate statistical power and information to adjust for
potential confounding factors.
Patient-level data from electronic databases present
challenges in terms of accuracy and completeness of the
study variables of interest. Although we sought to miti-
gate potential sources of bias in the conduct of this
study, some limitations remain, including potential mis-
classification of exposure and/or outcome, the potential
for residual confounding, and aspects of competing
risks. Exclusion of patients with incomplete information
and thorough matching process may have resulted in se-
lection of optimally-treated patients. Some residual con-
founding would be due to the non-availability of
duration of diabetes data and data on socio-economic
status, although we have adjusted for the pre-exposure
time. Information on socio-economic status was likely to
be relevant in this study given that treatment with EBID
is more expensive and most likely that only individuals
with good insurance would be able to afford it. Another
important aspect is the failure to adequately adjust
for the “bias due to indication”, which is very likely in
the insulin-treated patients. Patients treated with insu-
lin are generally deemed to have relatively poor health
condition, which is difficult to adequately adjust for in
clinical epidemiological studies, and we did not have
complete data on the exact insulin doses to correctlyadjust for it. Finally, the possibility of non-random pre-
scription pattern leading to confounding by indication
is impossible to overcome and cannot be excluded.
However, we conducted analyses among patients with-
out history of cardiovascular and renal diseases, and a
balanced distribution of age and glycaemic level at the
start of the cohort.
Diagnosis of CV disease using ICD-9 codes may not
always represent a clinical diagnosis of the disease. How-
ever, the ICD-9 diagnosis-coded case definitions adhered
to in this study have been applied in previous studies
using the same or a similar database [35,36]. Prior stud-
ies have indicated that the estimated predictive value of
administrative data for identifying CV endpoints is high
(95% for acute MI and stroke). In studies based on
administrative data, misclassification of events may be
assumed to be non-differential with respect to exposure,
providing a bias in the hazard estimate toward the null
value that might obscure an association between exena-
tide and vascular risk. Another common weakness in
pharmaco-epidemiological studies based on electronic
primary care data, is the incompleteness on prescription
information longitudinally for specific therapies. In our
study, one of the primary inclusion criteria was to en-
sure a minimum of two consecutive prescriptions for
insulin or exenatide, and the number of available pre-
scriptions with dates during follow-up was well tracked.
Due to the non-availability of mortality data, we could
not conduct risk analyses on death due to cardiovascular
diseases and all-cause mortality.
Conclusions
Development of CV disease is one of the major complica-
tions of T2DM. The chronic hyperglycaemic state is often
accompanied by dyslipidaemia, hypertension, low-grade
systemic inflammation and oxidative stress, which collect-
ively result in a high risk of micro- and macrovascular
complications. Our population-based study provided evi-
dence for the potential CV benefits of treatment with the
GLP-1R agonist exenatide, while used in combination with
conventional anti-diabetic therapies in reducing risks of
HF, MI and stroke in patients with T2DM. While the
confirmatory results from clinical trials are awaited, our
epidemiological study provides much needed guiding in-
formation to the clinicians who are trying to balance the
optimum glycaemic control along with management of
CV risks in patients with T2DM.
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